Angle PLC on Friday said it is has presented data that highlights the potential of a new assay for lung cancer patients, and will soon present positive data for a breast cancer testing kit.

Shares in Angle were trading 16% higher at 11.57 pence on Friday in London.

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research’s Special Conference, ’Liquid Biopsy: From Discovery to Clinical Implementation’, which runs in San Diego from Wednesday to Saturday.

Angle said its CYC PD-L1 assay enables longitudinal monitoring of ’Programmed Death Ligand-1’ status in lung cancer patients, and may help to advance personalised treatment.

In its ongoing longitudinal study, Angle said, the assay identified circulating tumour cells or CTCs in 91% of 32 metastatic lung cancer patients.

PD-L1 positive CTCs were observed in 72% of patients with a PD-L1 positive tissue biopsy and in 27% of patients with a PD-L1 negative tissue biopsy, Angle said.

‘The results presented in this study demonstrate the potential for the development of CTC-based dynamic PD-L1 testing to advance personalised treatment for metastatic lung cancer patients,’ Angle said.

‘We are pleased to have presented this poster...The results of this study further demonstrate the utility of ANGLE’s PD-L1 assay,’ said Chief Scientific Officer Karen Miller. ‘Longitudinal monitoring is essential to the advancement of personalised medicine, and we look forward to contributing to this advancement and supporting the needs of our pharma customers through development of our CTC-based assays.’

Also, Angle and cell imaging company BioView Ltd have been co-developing an end-to-end assay kit to evaluate HER2 gene amplification and protein expression in CTCs harvested using from metastatic breast cancer patients’ blood, using Angle’s Parsortix system.

Angle said a study has identified cases in a cohort of 43 MBC patients where HER2 status had changed over time with originally HER2 negative patients had become HER2 positive.

The results showcase the development of a scoring system for HER2 expression which could complement the current standard use of tumour tissue to assess HER2 status, Angle said.

‘The results Angle will present...are an important milestone in our development programme,’ commented BioView’s Chief Scientific Officer Chassidy Johnson. ‘The results highlight the ability and robust analytical performance of the developed HER2 CTC assay to detect ranges of HER2 expression therefore potentially identifying patients that could benefit from anti-HER2 therapy as well as newer HER2-targeted ADCs.’

Copyright 2024 Alliance News Ltd. All Rights Reserved.